Loading…
Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
Introduction Allogeneic hematopoietic cell transplant (HCT) in adults ≥70 years is increasing with improved donor availability, newer disease therapies, and increasingly preserved fitness. Registry studies indicate that these older patients represent a frailer transplant population overall, with a h...
Saved in:
Published in: | Blood 2024-11, Vol.144, p.1042-1042 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Introduction
Allogeneic hematopoietic cell transplant (HCT) in adults ≥70 years is increasing with improved donor availability, newer disease therapies, and increasingly preserved fitness. Registry studies indicate that these older patients represent a frailer transplant population overall, with a historical 1-year non-relapse mortality (NRM) at around 25%.
BMT CTN 1703 enrolled adult patients undergoing allogeneic HCT with a matched related donor, or 7-8/8 HLA-matched unrelated donor and reduced intensity conditioning (Bolanos-Meade NEJM, 2023). Patients were randomized 1:1 to post-transplant cyclophosphamide, tacrolimus, and mycophenolate (PTCy/Tac/MMF) or tacrolimus and methotrexate (Tac/MTX) and the primary endpoint was 1-year GVHD/relapse or progression-free survival (GRFS). Overall, a superior 1-year GRFS rate was seen with PTCy/Tac/MMF, however NRM and overall survival (OS) did not differ between treatment arms. We report here, a post hoc analysis of patients ≥70 years randomized on the BMT CTN 1703 protocol.
Methods
Patients ≥70 years randomized on BMT CTN 1703 (PTCy=43, Tac/MTX=53; N=96) were included. The primary endpoint of this post-hoc analysis was 1y-GRFS. Secondary endpoints included infections, engraftment, incidence/severity of acute and chronic GVHD, relapse/progression, adverse events, NRM, and OS in these patients.
Results
Baseline characteristics were balanced between the two treatment arms. Median age at transplant between patients treated with PTCy/Tac/MMF and Tac/MTX was 72 years (70.1-78.6y) and 73 years (70.1-77.4) respectively. In similar order 88% and 85% underwent HCT with HLA matched unrelated donor, and 46% and 40% received Flu/Mel conditioning, which was the most common conditioning regimen. Multivariate Cox model of GRFS revealed that the PTCy/Tac/MMF maintained superiority over Tac/MTX with a significantly lower hazard of GRFS (0.341, 95% CI 0.184-0.633, p500mm3) by day 28 was similar between arms (92.8% vs 92.8%, p=0.85). From a toxicity standpoint, with PTCy/Tac/MMF or Tac/MTX, rates of grade 3 infections at 6 months were 4.6% and 11.8%, rates of Grade 3-5 cardiac eve |
---|---|
ISSN: | 0006-4971 |
DOI: | 10.1182/blood-2024-193827 |